Danaher Corporation (DHR)

Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added concern.

Danaher Corporation (NYSE:DHR ) TD Cowen 45th Annual Health Care Conference Call March 5, 2025 10:30 AM ET Company Participants Rainer Blair – President and Chief Executive Officer Conference Call Par...

DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.

Though not as safe a bet as safe-haven assets like precious metals, value stocks are nonetheless an enticing option for investors when the market gets bumpy. An undervalued company that has excellent ...

Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company's strategic...

Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend...

I started investing with a modest $4,000, now growing it into a 23-stock portfolio. The median net worth varies by age, but most can invest $10,000 for growth. The goal here isn't to push random picks...

Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.

DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.